Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02187302 |
| Title | CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Cerulean Pharma Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |